当前位置: 首页 >> 检索结果
共有 15190 条符合本次的查询结果, 用时 1.3811557 秒

61. A Phase 3 Trial of Brepocitinib in Dermatomyositis.

作者: Ruth Ann Vleugels.;Julie J Paik.;Iazsmin Bauer Ventura.;Aaron R Mangold.;Prateek C Gandiga.;Anna Haemel.;Hector Chinoy.;Yessar M Hussain.;Kumaraswamy Sivakumar.;Griger Zoltan.;Eun Bong Lee.;Francisca Bozan.;Chung-Yuan Hsu.;Alisa Femia.;Mazen M Dimachkie.;Michelle S Min.;Tahseen Mozaffar.;Christina Charles-Schoeman.;David R Fernandez.;Oluwakemi Onajin.;Raquel Marques.;Galina Marder.;Floranne Ernste.;Elena Schiopu.;Jason Sluzevich.;David Pearson.;Stephen Lindsey.;Michael Luggen.;Michael R Bubb.;Erin Boh.;Rashmi Maganti.;Latisha Heinlen.;Katharina S Shaw.;Matthew D Cascino.;Paul N Mudd.;Jiri Vencovsky.;Anthony P Fernandez.;David Fiorentino.;Lisa Christopher-Stine.;Victoria P Werth.;Rohit Aggarwal.; .
来源: N Engl J Med. 2026年
Brepocitinib is a first-in-class, oral, selective TYK2-JAK1 inhibitor that blocks cytokine signaling, which has been implicated in dermatomyositis.

62. Left Atrial Appendage Closure - Should Recommendations Be Expanded?

作者: Gregory M Marcus.
来源: N Engl J Med. 2026年

63. Advanced Therapy for Intermediate-Risk Pulmonary Embolism.

作者: Alex C Spyropoulos.;Suresh Vedantham.
来源: N Engl J Med. 2026年

64. Paving the Road toward Targeted Lipid Lowering.

作者: Jeffrey L Probstfield.;Kelley R H Branch.
来源: N Engl J Med. 2026年394卷14期1443-1444页

65. Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease.

作者: Yong-Joon Lee.;Seung-Jun Lee.;Jin Won Kim.;Sang-Hyup Lee.;Gwang-Sil Kim.;Jae Hyoung Park.;Jin-Man Cho.;Woong Chol Kang.;Hyuck-Jun Yoon.;Won Ho Kim.;Seung-Jin Lee.;Jin Bae Lee.;Ji-Yong Jang.;Sanghoon Shin.;Ik Hyun Park.;Sung Uk Kwon.;Sunwon Kim.;Sung-Jin Hong.;Chul-Min Ahn.;Jung-Sun Kim.;Young-Guk Ko.;Donghoon Choi.;Myeong-Ki Hong.;Yangsoo Jang.;Byeong-Keuk Kim.; .
来源: N Engl J Med. 2026年394卷14期1365-1375页
Despite guideline recommendations, evidence from randomized trials evaluating the appropriate low-density lipoprotein (LDL) cholesterol target for secondary prevention in patients with atherosclerotic cardiovascular disease remains limited.

66. The Age Illusion - Limitations of Chronologic Age in Medicine.

作者: Martin G Lee.
来源: N Engl J Med. 2026年394卷13期1251-1253页

67. Hepatic Arterial Buffer Response.

作者: Tushar Kumar.;Sakura M Noda.
来源: N Engl J Med. 2026年394卷13期1325页

68. Physicians, Corporatization, and the Unmeasured Quality of Care.

作者: Lawrence P Casalino.
来源: N Engl J Med. 2026年394卷13期1249-1251页

69. Therapy's Conversion - Chiles v. Salazar's Threat to Mental Health Treatment and Standards of Care.

作者: Michael R Ulrich.
来源: N Engl J Med. 2026年394卷13期1253-1255页

70. Health Insurance after Corporatization - What Next?

作者: Leemore Dafny.
来源: N Engl J Med. 2026年394卷6期521-523页

72. Aortitis Due to Large-Vessel Vasculitis.

作者: Hsien-Tzung Liao.;Ching-Lan Wu.
来源: N Engl J Med. 2026年394卷6期588页

74. More on Cold Perfusion vs. Static Cold Storage of Deceased-Donor Kidneys. Reply.

作者: Cyril Moers.;Rutger J Ploeg.
来源: N Engl J Med. 2026年394卷6期623页

75. More on Cold Perfusion vs. Static Cold Storage of Deceased-Donor Kidneys.

作者: Badri Shrestha.
来源: N Engl J Med. 2026年394卷6期622-623页

76. Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer. Reply.

作者: Xiuning Le.;Jan Christoph Brase.;Weichao Bao.
来源: N Engl J Med. 2026年394卷6期622页

77. Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.

作者: Liying Wu.;Jinyu Yu.;Wei Liu.
来源: N Engl J Med. 2026年394卷6期621-622页

78. Sacituzumab Govitecan in Advanced Triple-Negative Breast Cancer. Reply.

作者: Javier Cortés.;Sara M Tolaney.
来源: N Engl J Med. 2026年394卷6期620-621页

79. Sacituzumab Govitecan in Advanced Triple-Negative Breast Cancer.

作者: Timothée Olivier.;John-John B Schnog.
来源: N Engl J Med. 2026年394卷6期620页

80. Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3. Reply.

作者: Luke J Laffin.;Stephen J Nicholls.;Steven E Nissen.
来源: N Engl J Med. 2026年394卷6期619-620页
共有 15190 条符合本次的查询结果, 用时 1.3811557 秒